Matthew Kurian, Assistant Professor of Medicine at the University of Kentucky College of Medicine and Physician at St. Elizabeth Healthcare, shared a post on LinkedIn:
“ESMO25 | evERA Trial, All-Oral Option in HR⁺/HER2⁻ mBC (Post-CDK4/6)
The Phase III evERA trial (n = 373) tested Giredestrant + Everolimus vs SOC endocrine + Everolimus in ER⁺/HER2⁻ mBC after CDK4/6i.
Arms: 183 in Giredestrant arm at 30 mg + Everolimus 10 mg vs 190 in Exemestane/Fulvestrant/Tamoxifen + Everolimus.
Stratified by ESR1 status, visceral disease, prior fulvestrant.
Results:
- ITT PFS: 8.8 mo vs 5.5 mo (HR 0.56 )
- ESR1-mut PFS: 9.99 mo vs 5.45 mo (HR 0.38 )
- ORR: 24% vs 12%; DOR ~12.7 mo vs 7.7 mo
- OS trend: HR 0.62 (ESR1-mut)
Safety:
- Stomatitis 47%, diarrhea 27%, anemia 24%; bradycardia ~4%. No new signals – AE discontinuation 17% vs 12%.
Why it matters:
- All-oral SERD + mTOR → distinct path beyond CDK4/6 reuse
- Strongest in ESR1-mut but benefit seen ITT
- Convenient, biologically rational option
Would you use this before CDK4/6 re-challenge?”
Follow ESMO 2025 news on OncoDaily.